Company & Sponsor Intelligence
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed1
Countries2
Therapeutic footprint
epilepsyunclassified
Indexed studies
NCT00280059Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
epilepsy · BelgiumPHASE3
epilepsy · BelgiumPHASE3
NCT00372528An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
epilepsy · CanadaPHASE3
epilepsy · CanadaPHASE3
NCT00785772A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
epilepsy · JapanPHASE4
epilepsy · JapanPHASE4
NCT01262677Once-A-Day Pregabalin For Partial Seizures
unclassified · United StatesPHASE3
unclassified · United StatesPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →